126 results
POS AM
SYRE
Spyre Therapeutics Inc.
26 Mar 24
Prospectus update (post-effective amendment)
6:30pm
and Immedica dated March 2021.
The milestone payments under the Immedica APA are contingent on formal reimbursement decisions by national authorities … -party coverage and reimbursement policies.
We may face criminal liability or other consequences for violations of U.S. and foreign trade regulations
POS AM
SYRE
Spyre Therapeutics Inc.
14 Mar 24
Prospectus update (post-effective amendment)
4:12pm
between us and Immedica dated March 2021.
The milestone payments under the Immedica APA are contingent on formal reimbursement decisions by national … .
We may be unable to offer products at competitive prices due to unfavorable pricing regulations and/or third-party coverage and reimbursement policies
POS AM
elt6vel6 z4
5 Mar 24
Prospectus update (post-effective amendment)
5:15pm
8-K
EX-99.1
o6kxlnn6ys2 nu5jud
29 Feb 24
Spyre Therapeutics Reports Fourth Quarter and Full Year 2023 Financial Results and Provides Corporate Update
4:14pm
424B3
niwnz3wc 1n
6 Feb 24
Prospectus supplement
9:37pm
8-K
EX-3.1
edj7ca44nb
5 Feb 24
Entry into a Material Definitive Agreement
7:36am